About akebia therapeutics inc - AKBA
Akebia Therapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapeutics for patients with kidney diseases. The firm is also involved in the development and commercialization of drugs for the treatment of renal and metabolic disorders. Its products include Auryxia and Vafseo. The company was founded by Joseph H. Gardner, John M. Rice, Michael E. Pape, Josh P. Fairbank, and Robert A. Shalwitz on February 27, 2007 and is headquartered in Cambridge, MA.
AKBA At a Glance
Akebia Therapeutics, Inc.
245 First Street
Cambridge, Massachusetts 02142
| Phone | 1-617-871-2098 | Revenue | 236.20M | |
| Industry | Pharmaceuticals: Major | Net Income | -5,345,000.00 | |
| Sector | Health Technology | 2025 Sales Growth | 47.457% | |
| Fiscal Year-end | 12 / 2026 | Employees | 194 | |
| View SEC Filings |
AKBA Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | 1.753 |
| Price to Book Ratio | 13.104 |
| Price to Cash Flow Ratio | 6.09 |
| Enterprise Value to EBITDA | 17.917 |
| Enterprise Value to Sales | 1.879 |
| Total Debt to Enterprise Value | 0.487 |
AKBA Efficiency
| Revenue/Employee | 1,217,505.155 |
| Income Per Employee | -27,551.546 |
| Receivables Turnover | 5.022 |
| Total Asset Turnover | 0.791 |
AKBA Liquidity
| Current Ratio | 1.552 |
| Quick Ratio | 1.457 |
| Cash Ratio | 1.145 |
AKBA Profitability
| Gross Margin | 82.755 |
| Operating Margin | 9.949 |
| Pretax Margin | -1.575 |
| Net Margin | -2.263 |
| Return on Assets | -1.79 |
| Return on Equity | N/A |
| Return on Total Capital | -2.147 |
| Return on Invested Capital | -3.157 |
AKBA Capital Structure
| Total Debt to Total Equity | 663.287 |
| Total Debt to Total Capital | 86.899 |
| Total Debt to Total Assets | 57.44 |
| Long-Term Debt to Equity | 540.368 |
| Long-Term Debt to Total Capital | 70.795 |